Page last updated: 2024-08-21

pyrazines and Kidney Failure

pyrazines has been researched along with Kidney Failure in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.56)	18.2507
2000's	21 (32.81)	29.6817
2010's	41 (64.06)	24.3611
2020's	1 (1.56)	2.80

Authors

Authors	Studies
Balaratnam, G; Dixon, S; Green, M; Lehrer-Graiwer, J; Marbury, T; Preston, RA; Washington, C	1
Cao, ZG; Liu, M; Zhou, HW	1
An, G; Deng, SH; Feng, XY; Hao, M; Li, F; Qiu, LG; Sui, WW; Wang, YF; Xu, Y	1
Dimopoulos, MA; Kastritis, E; Terpos, E	1
Joseph, C; Ribeiro, A; Seikaly, M; Thach, L; Twombley, K	1
Bertsch, U; Blau, IW; Bos, GM; Croockewit, S; Duehrsen, U; el Jarari, L; Goldschmidt, H; Hänel, M; Jie, KS; Kersten, MJ; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; van de Velde, H; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Weisel, K; Wijermans, P; Wittebol, S; Zweegman, S	1
Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L	1
Alloway, RR; Cardi, M; Ejaz, NS; Girnita, AL; Mogilishetty, G; Sadaka, B; Shields, AR; Woodle, ES	1
Scheen, AJ; Van Gaal, LF	1
Czock, D; Hartmann, B; Keller, F	1
Delimpasi, S; Dimopoulos, MA; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Konstantopoulos, K; Kyrtsonis, MC; Michael, M; Michalis, E; Parcharidou, A; Pouli, A; Repousis, P; Symeonidis, A; Terpos, E; Vassou, A	1
San Miguel, JF	1
Aubert, O; Durrbach, A; Francois, H; Gauthe, R; Obada, EN; Suberbielle, C	1
Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S	1
Carr, MC; Handelsman, Y; Jones-Leone, A; Leiter, LA; Scott, R; Stewart, M; Yang, F	1
Becker, S; Brodt, HR; de Leuw, P; Grünewald, T; Kann, G; Kempf, VA; Keppler, OT; Stephan, C; Vogl, T; Wolf, T; Zacharowski, K	1
Arnulf, B; Deraedt, W; Esseltine, DL; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, P; van de Velde, H	1
Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S	1
Advani, A; Advani, SL; Azizi, PM; Batchu, SN; Bowskill, BB; Brijmohan, AS; Lee, WL; Liu, Y; Majumder, S; Thai, K; White, KE	1
An, N; Chen, SL; Huang, ZX; Li, X; Shen, M	1
Dimopoulos, MA; Kastritis, E; Rajkumar, SV	1
Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L	1
Bladé, J; Cibeira, MT; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH	1
Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Dentamaro, T; Fratoni, S; Giovannini, M; Niscola, P; Santeusanio, G; Scaramucci, L; Siniscalchi, A; Tendas, A	1
Boucher, BJ	1
Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F	1
Cross, LB; Gentry, C; Gross, B; McFarland, MS; Patel, UP; Tunney, J	1
Decaux, O; Karras, A	1
Duan, MH; Jiao, L; Li, J; Shen, T; Zhang, W; Zhao, YQ; Zhou, DB	1
Alexandrescu, DT; Dasanu, CA	1
Al Diab, AR; Al Momen, AK; Aleem, A; Niaz, F; Qayum, A	1
Ludwig, H; Zojer, N	1
Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E	1
Cohen, LJ; Humphreys, BD; Laubach, JP; Rennke, HG	1
Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P	1
Anderson, K; Laubach, J; Richardson, P	1
Fujisaki, T; Kan, S; Murakami, H; Muta, T; Nakanishi, H; Senba, S; Ueda, Y; Yasunaga, M	1
Akimoto, T; Hamano, Y; Hanawa, S; Imai, T; Inoue, M; Kotoda, A; Kusano, E; Matsuyama, T; Muto, S; Ozawa, K; Saito, O; Ueda, M; Uehara, E; Yoshizawa, H; Yumura, W	1
Aydin, F; Bayik, M; Firatli-Tuglular, T; Kaygusuz, I; Toptas, T; Uzay, A	1
Baburaj, R; Edwards, CM; Lestner, JM	1
Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E	1
Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL	1
Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF	1
Knop, S	1
Morgan, G	1
Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T	1
Cao, XX; Duan, MH; Kang, WY; Li, J; Zhang, W; Zhou, DB	1
Guo, M; Hu, KX; Kang, Y; Qiao, JH; Sun, QY; Yu, CL; Zhao, YY	1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E	1
Suzuki, K	1
Abbas, J; Costa, LJ; Kang, Y; Ortiz-Cruz, KL; Stuart, RK	1
Gemba, M; Kohda, Y	1
Reddy, GK	1
Alexanian, R; Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Jagannath, S; Nix, D; Orlowski, RZ; Richardson, PG; Singhal, S; Srkalovic, G	1
Armando, S; Nozza, A; Siracusano, L	1
Gupta, V; Malani, AK; Rangineni, R	1
Chanan-Khan, AA; Kaufman, JL; Lonial, S; Mehta, J; Miller, KC; Munshi, NC; Richardson, PG; Schlossman, R; Singhal, S; Tariman, J	1
Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M	1
Bergman, AJ; Cote, J; Gottesdiener, K; Herman, GA; Marbury, T; Smith, W; Swan, SK; Wagner, J; Yi, B	1
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; San-Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA	1
Gertz, MA	1
Barmparousi, D; Dimopoulos, MA; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Psimenou, E; Roussou, M; Terpos, E	1
Gladney, SP; Kaufman, JL; Lonial, S	1
Beyer, KH; Gelarden, RT; Knutson, DW; Vary, JE; Vesell, ES; Ward, TD	1

Reviews

11 review(s) available for pyrazines and Kidney Failure

Article	Year
Current treatments for renal failure due to multiple myeloma. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Transplantation; Multiple Myeloma; Pyrazines; Renal Insufficiency	2013
Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, Volume: 22, Issue:7 Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia	2008
Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008, Volume: 22, Issue:8 Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide	2008
The spectrum of kidney involvement in lymphoma: a case report and review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 56, Issue:6 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Prognosis; Pyrazines; Renal Insufficiency; Rituximab; Treatment Outcome	2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33 Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous	2010
Multiple myeloma. Annual review of medicine, 2011, Volume: 62 Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2011
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert review of hematology, 2012, Volume: 5, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide	2012
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome	2012
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and experimental nephrology, 2012, Volume: 16, Issue:5 Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide	2012
Current therapy of myeloma induced renal failure. Leukemia & lymphoma, 2008, Volume: 49, Issue:5 Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide	2008
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia & lymphoma, 2008, Volume: 49, Issue:5 Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency; Treatment Outcome	2008

Trials

11 trial(s) available for pyrazines and Kidney Failure

Article	Year
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment. Journal of clinical pharmacology, 2021, Volume: 61, Issue:4 Topics: Adult; Aged; Area Under Curve; Benzaldehydes; Body Mass Index; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Half-Life; Hematologic Agents; Hepatic Insufficiency; Humans; Male; Middle Aged; Pyrazines; Pyrazoles; Renal Insufficiency	2021
[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:1 Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency	2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica, 2014, Volume: 99, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Transplantation, Autologous; Treatment Outcome	2014
Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:12 Topics: Adult; Animals; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft Rejection; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Pyrazines; Rabbits; Renal Insufficiency; Rituximab; Treatment Outcome	2013
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes care, 2014, Volume: 37, Issue:10 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica, 2015, Volume: 100, Issue:5 Topics: Administration, Cutaneous; Administration, Intravenous; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Renal Insufficiency; Treatment Outcome	2015
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Renal Insufficiency; Treatment Outcome	2009
[Clinical study of bortezomib for treating multiple myeloma with renal impairment]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency	2012
New developments with bortezomib in treating multiple myeloma. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome	2004
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood, 2007, Aug-01, Volume: 110, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous	2007
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia, 2008, Volume: 22, Issue:4 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Survival Analysis; Treatment Outcome	2008

Other Studies

42 other study(ies) available for pyrazines and Kidney Failure

Article	Year
[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4 Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome	2013
Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience. Pediatric transplantation, 2013, Volume: 17, Issue:7 Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Hypotension; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Male; Methylprednisolone Hemisuccinate; Patient Compliance; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Rituximab; Treatment Outcome	2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies	2013
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. Revue medicale de Liege, 2013, Volume: 68, Issue:10 Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles	2013
Time of effect duration and administration interval for sitagliptin in patients with kidney failure. European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:2 Topics: Half-Life; Humans; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Time Factors; Triazoles	2014
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome	2014
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment? Haematologica, 2014, Volume: 99, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency	2014
Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant. Transplantation, 2014, May-15, Volume: 97, Issue:9 Topics: Adult; Aged; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Kidney Transplantation; Male; Middle Aged; Neutrophils; Preoperative Period; Prospective Studies; Proteasome Inhibitors; Pyrazines; Renal Insufficiency; Steroids; Time Factors; Treatment Outcome	2014
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide	2014
Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet (London, England), 2015, Apr-11, Volume: 385, Issue:9976 Topics: Adult; Amides; Amiodarone; Anti-Infective Agents; Antiviral Agents; Blood Vessels; Critical Care; Fibrin Fibrinogen Degradation Products; Hemorrhagic Fever, Ebola; Humans; Intubation, Intratracheal; Male; Multiple Organ Failure; Patient Isolation; Peptide Fragments; Pulmonary Edema; Pyrazines; Radiography, Thoracic; Renal Insufficiency; Respiratory Insufficiency	2015
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia, 2015, Volume: 29, Issue:5 Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome	2015
Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms. Diabetes, 2016, Volume: 65, Issue:5 Topics: Acetamides; Acetates; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Podocytes; Prodrugs; Protein Processing, Post-Translational; Pyrazines; Receptors, Epoprostenol; Renal Insufficiency; RNA Interference	2016
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency]. Zhonghua nei ke za zhi, 2016, Oct-01, Volume: 55, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome	2016
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies	2008
Bortezomib-related colon mucositis in a multiple myeloma patient. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colonic Diseases; Humans; Male; Middle Aged; Mucositis; Multiple Myeloma; Pyrazines; Renal Insufficiency	2009
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:2 Topics: Amiodarone; Contraindications; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pyrazines; Renal Insufficiency; Rhabdomyolysis; Simvastatin; Sitagliptin Phosphate; Triazoles; United Kingdom; United States	2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome	2009
Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:7 Topics: Ambulatory Care Facilities; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Utilization Review; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Function Tests; Medication Errors; Pharmacists; Private Sector; Professional Role; Pyrazines; Renal Insufficiency; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States	2009
[Update in multiple myeloma: international criteria for treatment response and renal complications]. La Revue de medecine interne, 2009, Volume: 30, Issue:12 Topics: Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; France; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Immunologic Factors; International Cooperation; Kidney Diseases; Multiple Myeloma; Practice Guidelines as Topic; Prevalence; Pyrazines; Renal Dialysis; Renal Insufficiency; Sensitivity and Specificity; Societies, Medical	2009
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4 Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation	2010
Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recovery of Function; Renal Insufficiency; Time Factors; Treatment Outcome	2010
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays	2010
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leukemia research, 2010, Volume: 34, Issue:10 Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide	2010
[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatine; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency	2011
Renal failure caused by plasma cell infiltration in multiple myeloma. Clinical and experimental nephrology, 2011, Volume: 15, Issue:4 Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Female; Humans; Kidney; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Renal Insufficiency	2011
Bortezomib in patients with renal impairment. Hematology (Amsterdam, Netherlands), 2011, Volume: 16, Issue:4 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Diarrhea; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Survival Analysis	2011
Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity? British journal of hospital medicine (London, England : 2005), 2011, Volume: 72, Issue:7 Topics: Aged; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles	2011
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia & lymphoma, 2011, Volume: 52, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome	2011
[Current perspectives in the treatment of multiple myeloma - news and views]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:13 Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous	2012
Myeloma: diagnosis complications and supportive care. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid	2012
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting	2012
Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leukemia & lymphoma, 2012, Volume: 53, Issue:12 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Induction Chemotherapy; Male; Middle Aged; POEMS Syndrome; Pyrazines; Renal Insufficiency; Treatment Outcome	2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine	2013
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. European journal of haematology, 2012, Volume: 89, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome	2012
Enhancement of protein kinase C activity and chemiluminescence intensity in mitochondria isolated from the kidney cortex of rats treated with cephaloridine. Biochemical pharmacology, 2002, Aug-01, Volume: 64, Issue:3 Topics: Animals; Cephaloridine; Cephalosporins; Kidney Cortex; Luminescent Measurements; Male; Mitochondria; Protein Kinase C; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renal Insufficiency	2002
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 2005, Mar-15, Volume: 103, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome	2005
Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clinical therapeutics, 2006, Volume: 28, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Renal Insufficiency	2006
Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta haematologica, 2006, Volume: 116, Issue:4 Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Salvage Therapy; Treatment Outcome	2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood, 2007, Mar-15, Volume: 109, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies	2007
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes care, 2007, Volume: 30, Issue:7 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles	2007
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:1 Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Pyrazines; Renal Dialysis; Renal Insufficiency; Thalidomide	2008
Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency. Journal of clinical pharmacology, 1993, Volume: 33, Issue:6 Topics: Adult; Aged; Blood Glucose; Cholesterol; Electrolytes; Female; Guanidines; Humans; Hydrochlorothiazide; Male; Middle Aged; Pyrazines; Renal Insufficiency; Single-Blind Method; Triglycerides; Urea	1993